Nanobiotix Equity Raise Backs JNJ-1900 Progress And Volatile Share Rally

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

• Nanobiotix (ENXTPA:NANO) has closed a global equity offering to fund continued development of its lead product candidate JNJ-1900 (NBTXR3).

• The raise followed promising early results from a Johnson & Johnson sponsored Phase 2 trial in stage 3 inoperable non small cell lung cancer, presented at ESTRO 2026.

• The company plans to use the new capital to progress its oncology pipeline, with a focus on JNJ-1900 (NBTXR3).

For investors tracking ENXTPA:NANO, the combination of fresh equity funding and new clinical data comes after a very large 1 year share price gain and a 79.2% return year to date, with the stock last closing at €34.04. Even with a decline of 6.6% over the past week, the share price is still up 20.5% over the past month and more than 6x over three years, highlighting the stock’s sensitivity to company specific news.

This latest funding round and the early readout from the Johnson & Johnson sponsored trial place attention on how Nanobiotix executes from here, both clinically and operationally. As more data from JNJ-1900 (NBTXR3) emerge and the new capital is deployed, investors will be watching for clarity on development timelines, regulatory interactions and any future partnerships or financing decisions.

Stay updated on the most important news stories for Nanobiotix by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Nanobiotix.

See which insiders are buying and buying and selling Nanobiotix following this latest news.

The €85 million global equity raise signals that institutional and retail investors were prepared to supply fresh capital at a slight discount to the recent trading price, with ordinary shares priced around €33.60. That is relatively close to the last close of €34.04, which suggests there was sufficient demand to clear the book without a steep price cut. The inclusion of American Depositary Shares and pre-funded warrants also points to interest from US-based investors and from buyers looking to lock in exposure while limiting near-term cash outlay. Taken together with the early Phase 2 lung cancer data, the funding round indicates that the market is currently prepared to finance Nanobiotix’s late-stage pipeline and earlier platforms, but at the cost of additional dilution for existing shareholders.

How This Fits Into The Nanobiotix Narrative

• The raise supports the existing catalyst that JNJ-1900 (NBTXR3) could plug into established radiotherapy pathways, by providing capital to keep late-stage trials and potential partnering work on track.

• Issuing new equity shortly after earlier comments about extended cash visibility may challenge the idea that future milestones can be pursued with fewer equity raises, so investors may revisit assumptions about dilution.

• The offering terms, including pre-funded warrants and the focus on US-listed securities, bring an additional angle around investor mix and capital structure that is not fully reflected in the original narrative.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Nanobiotix to help decide what it’s worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Analysts have flagged that Nanobiotix has a highly volatile share price over the past 3 months compared to the French market, so equity raises can have an outsized impact on short-term returns.

• ⚠️ The company has negative shareholders’ equity, which adds balance-sheet risk and makes the terms and timing of any future capital raises more important.

• 🎁 The stock is assessed as trading at a discount to an internal estimate of fair value, which some investors may see as a cushion if the clinical and partnership plans progress as intended.

• 🎁 Earnings are forecast by analysts to grow quickly, so investors who accept execution risk may view today’s dilution as a trade-off for funding potential future growth.

What To Watch Going Forward

Next, investors will likely focus on how Nanobiotix allocates the new funds across JNJ-1900 (NBTXR3), the NANORAY-312 study, and the Nanoprimer platform, and whether management provides clearer timelines and milestones tied to this capital. It will also be important to watch any follow-up data from the CONVERGE Phase 2 lung trial and other JNJ-1900 programs, plus signals from Johnson & Johnson on the scope of the collaboration. Given the reliance on external financing, investors may also monitor cash burn, future equity or royalty deals and whether share-price volatility remains elevated around clinical or regulatory events.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Nanobiotix, head to the community page for Nanobiotix to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NANO.PA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com